12.16
5.52%
-0.71
Greenwich Lifesciences Inc stock is traded at $12.16, with a volume of 46,666.
It is down -5.52% in the last 24 hours and down -1.86% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$12.87
Open:
$12.9
24h Volume:
46,666
Relative Volume:
1.47
Market Cap:
$159.84M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-17.37
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+0.83%
1M Performance:
-1.86%
6M Performance:
-18.00%
1Y Performance:
+33.23%
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
12.16 | 159.84M | 0 | -8.89M | -6.48M | -0.70 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) - Marketscreener.com
Long Term Trading Analysis for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 - GlobeNewswire
Greenwich LifeSciences expands trial sites in Germany - Investing.com India
Greenwich Lifesciences Announces Partnership with GBG in Germany for Flamingo-01 - Marketscreener.com
Greenwich LifeSciences CEO acquires $31,275 in common stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO acquires $31,275 in common stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares - MarketBeat
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus.com
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France - The Manila Times
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across France with Unicancer Network - StockTitan
Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock By Investing.com - Investing.com Australia
Insider Buying: Snehal Patel Increases Stake in Greenwich LifeSc - GuruFocus.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $24,750.00 in Stock - MarketBeat
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock - Investing.com India
Greenwich Lifesciences CEO Snehal Patel acquires $44,030 in stock By Investing.com - Investing.com Canada
Greenwich Lifesciences CEO Snehal Patel acquires $44,030 in stock - Investing.com
Greenwich LifeSciences CEO Snehal Patel buys $23,940 in stock By Investing.com - Investing.com Australia
Snehal Patel Buys 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock - MarketBeat
Greenwich LifeSciences CEO Snehal Patel buys $23,940 in stock - Investing.com India
(GLSI) Trading Report - Stock Traders Daily
Greenwich LifeSciences CEO buys $27,264 in company stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO buys $27,264 in company stock - Investing.com India
State Street Corp Raises Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel acquires $35,584 in stock By Investing.com - Investing.com Canada
Snehal Patel Purchases 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock - MarketBeat
Greenwich Lifesciences CEO Snehal Patel acquires $35,584 in stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update - MarketBeat
Insider Purchases Worth US$3.19m See Losses As Greenwich LifeSciences Market Value Drops To US$151m - Simply Wall St
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences (NASDAQ:GLSI) Reports Results of Annual Meeting - Defense World
Greenwich LifeSciences reports shareholder meeting outcomes By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Has $348,000 Stock Position in Vanguard International High Dividend Yield ETF (NASDAQ:VYMI) - Defense World
Maiden Holdings, Ltd. (NASDAQ:MHLD) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Invesco Dividend Achievers ETF (NASDAQ:PFM) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Sells 3,312 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Charles Schwab Investment Management Inc. Sells 1,210 Shares of Oak Valley Bancorp (NASDAQ:OVLY) - Defense World
Charles Schwab Investment Management Inc. Lowers Position in NexPoint Real Estate Finance, Inc. (NYSE:NREF) - Defense World
Charles Schwab Investment Management Inc. Increases Position in Fresenius Medical Care AG (NYSE:FMS) - Defense World
Charles Schwab Investment Management Inc. Has $351,000 Stock Holdings in Eos Energy Enterprises, Inc. (NASDAQ:EOSE) - Defense World
Seven Hills Realty Trust (NASDAQ:SEVN) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $515,000 Stake in Endava plc (NYSE:DAVA) - Defense World
Agenus Inc. (NASDAQ:AGEN) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):